3 CAR-T therapies and 1 bispecific antibody approved for follicular lymphoma, signaling ongoing advancements.
The treatment landscape for follicular lymphoma is evolving with the introduction of CAR-T therapies and bispecific antibodies. Three CAR-T options, including YESCARTA, BREYANZI, and KYMRIAH, have gained approval, while LUNSUMIO stands out as the first approved bispecific antibody for relapsed/refractory cases. These therapies offer varying benefits in accessibility and safety. Ongoing advancements in both treatment types signal a promising future for patients battling this slow-growing cancer.
September 16, 2024
3 Articles